Trial Profile
A pilot study to evaluate PSMA-Targeted 18F-DCFPyL PET/CT in patients with metastatic clear cell renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Piflufolastat F18 (Primary)
- Indications Renal cell carcinoma
- Focus Diagnostic use
- 12 May 2016 New trial record
- 10 May 2016 Results presented at the 111th Annual Meeting of the American Urological Association